Cargando…
Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The Royal Society
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485898/ https://www.ncbi.nlm.nih.gov/pubmed/37681498 http://dx.doi.org/10.1098/rsob.230322 |
| _version_ | 1785102885845991424 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10485898 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The Royal Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104858982023-09-09 Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. Open Biol Retractions The Royal Society 2023-09-08 /pmc/articles/PMC10485898/ /pubmed/37681498 http://dx.doi.org/10.1098/rsob.230322 Text en © 2023 The Authors. https://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, provided the original author and source are credited. |
| spellingShingle | Retractions Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. |
| title | Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. |
| title_full | Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. |
| title_fullStr | Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. |
| title_full_unstemmed | Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. |
| title_short | Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al. |
| title_sort | retraction: ‘hoxd-as1 confers cisplatin resistance in gastric cancer through epigenetically silencing pdcd4 via recruiting ezh2’ (2019), by ye et al. |
| topic | Retractions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485898/ https://www.ncbi.nlm.nih.gov/pubmed/37681498 http://dx.doi.org/10.1098/rsob.230322 |
| work_keys_str_mv | AT retractionhoxdas1conferscisplatinresistanceingastriccancerthroughepigeneticallysilencingpdcd4viarecruitingezh22019byyeetal |